Amoéba

Regulatory Filings • Nov 8, 2017

PRESS RELEASE

AMOEBA signs a Letter of Intent with H2O FACILITIES For the distribution of BIOMEBA in Switzerland

Lyon (France), Lancy (Switzerland), November 8 th, 2017 - AMOEBA (FR0011051598 - AMEBA), producer of a biological biocide capable of eliminating bacterial risk in water and wound care applications, announced today that it has signed a Letter of Intent (LOI) with H2O FACILITIES prior to entering into a definitive agreement regarding the distribution of its product in Switzerland, pending marketing authorization.

The signature of this agreement allows AMOEBA to extend its commercial cover in Europe for the distribution of the green biocide BIOMEBA in the regions of Geneva and Lausanne where the luxury goods industry and the tertiary sector are predominant.

H2O FACILITIES is a major player in water treatment and offers a global service on more than 300 cooling towers in the French-speaking region of Switzerland.

"We are very happy to be able to offer this innovative solution to our customers. We already know that some of them want to test the BIOMEBA product in order to treat the water of their towers in an ecological manner." said Didier MENOUD, GENERAL MANAGER of H2O FACILITIES.

"With this new LOI, AMOEBA continues to develop its commercial network in Europe. Switzerland is a country sensitive to environmental issues and water preservation. With BIOMEBA, we intend to provide a concrete solution to end-users." stated Fabrice PLASSON, CEO of AMOEBA.

About H2O FACILITIES:

H2O FACILITIES SA was founded by Mr Rittener, Mr Menoud and Mr Bezzoli, who have over 60 years' experience in the field of water treatment. The company includes about twenty qualified technicians, each equipped with a service van allowing quick and effective interventions. Our range of exclusive products FINEAMIN and SANICLINE covers all needs for the conditioning of domestic hot water networks, cooling towers, air conditioning and heating. More information on www.h2o-f.ch

About AMOEBA:

AMOEBA group's objective is to become the global leader in eliminating waterborne bacterial risk in water treatment and wound care applications. Our solutions represent alternatives to chemical products widely used in the cooling water treatment and the wound care market. In a global market for chemical biocides estimated to be worth EUR 21 bn(1) AMOEBA is focusing on the industrial cooling tower application estimated at EUR 1.7 bn(2). Similarly, in a global wound care market estimated at EUR 15.2bn(3), AMOEBA is targeting the chronic wound care market in the USA, estimated to be worth EUR 751 million(4). The use of Willaertia magna C2c Maky in health care products will be subject to FDA (Food and Drug Administration) clearance in the USA. AMOEBA's biological biocide for water treatment, BIOMEBA, has not yet been granted marketing authorization in the USA, Europe and Canada. AMOEBA is taking the required regulatory steps to be granted marketing authorization in those regions for the use of BIOMEBA in cooling water systems. Based in Chassieu (Lyon, France), AMOEBA is quoted on compartment C of the Euronext Paris stock exchange and joined the CAC® Small index on 21st September 2015. More information on www.amoeba-biocide.com.

(1): Sources combined by Amoeba from water treatment agencies, Freedonia, Eurostat and MarketsandMarkets

(2): Amoeba data combined from the following sources: DRIRE 2013, Eurostat, ARHIA 2013

(3) marketsandmarkets.com, "Wound Care Market by Product, Wound Type, End User - Global Forecast to 2021," 2016.

(4) BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017.

Contacts:

Amoéba

Nathalie COMBROUSSE Marketing Communication Manager Tel. : +33 (0)4 81 09 18 15 nathalie.combrousse@amoeba-biocide.com Actifin

Ghislaine GASPARETTO Financial Communication Tel. : +33 (0)1 56 88 11 11 ggasparetto@actifin.fr